Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 220-226

  Coste, Emmanuel ^a   Greig, Iain R ^b   Mollat, Patrick ^c   Rose, Lorraine ^a   Gray, Mohini ^d   Ralston, Stuart H ^a   Van 'T Hof, Rob J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Galapagos SASU   (France)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABD 328; ABD 345; ANTIINFLAMMATORY AGENT; COLLAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ABD345; ALKANONE; BIPHENYL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG STRUCTURE; JOINT DESTRUCTION; LOW DRUG DOSE; MACROPHAGE; MACROPHAGE CULTURE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN SYNTHESIS INHIBITION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; EXPERIMENTAL ARTHRITIS; IMMUNOLOGY; METABOLISM;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BIPHENYL COMPOUNDS; BONE RESORPTION; HEXANONES; MAP KINASE SIGNALING SYSTEM; MICE; NF-KAPPA B; RANK LIGAND; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 84918586086     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203700     Document Type: Article

References (38)

1. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-71.
2. Gohda J, Akiyama T, Koga T, et al. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 2005;24:790-9.
3. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
4. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
5. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-27.
6. Redlich K, Gortz B, Hayer S, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 2004;164:543-55.
7. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004;10:617-24.
8. Van't Hof RJ, Idris AI, Ridge SA, et al. Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors. J Bone Miner Res 2004;19:1651-60.
9. Idris AI, Mrak E, Greig I, et al. ABD56 causes osteoclast apoptosis by inhibiting the NFkappaB and ERK pathways. Biochem Biophys Res Commun 2008;371:94-8.
10. Idris AI, Coste E, Greig IR, et al. The biphenyl-carboxylate derivative ABD328 is a novel orally active antiresorptive agent. Calcif Tissue Int 2010;87:525-32.
11. Dempsey PW, Doyle SE, He JQ, et al. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209.
12. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132:344-62.
13. Greig IR, Idris AI, Ralston SH, et al. Development and characterization of biphenylsulfonamides as novel inhibitors of bone resorption. J Med Chem 2006;49:7487-92.
14. Greig IR, Coste E, Ralston SH, et al. Discovery of biphenylketones as dual modulators of inflammation and bone loss. Bioorg Med Chem Lett 2010;20:5548-51.
15. Idris AI, Krishnan M, Simic P, et al. Small molecule inhibitors of IkappaB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. FASEB J 2010;24:4545-55.
16. Idris AI, Greig IR, Bassonga-Landao E, et al. Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation. Endocrinology 2009;150:5-13.
17. De Launay D, Van De Sande MG, De Hair MJ, et al. Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Ann Rheum Dis 2012;71:415-23.
18. Darnay BG, Ni J, Moore PA, et al. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 1999;274:7724-31.
19. Feng X. Regulatory roles and molecular signaling of TNF family members in osteoclasts. Gene 2005;350:1-13.
20. Blonska M, Shambharkar PB, Kobayashi M, et al. TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation. J Biol Chem 2005;280:43056-63.
21. Shim JH, Xiao C, Paschal AE, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005;19:2668-81.
22. Lamothe B, Webster WK, Gopinathan A, et al. TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. Biochem Biophys Res Commun 2007;359:1044-9.
23. Walczak H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol Rev 2011;244:9-28.
24. Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int 2011;22:421-33.
25. Van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3104-12.
26. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
27. Feldmann M, Brennan FM, Paleolog E, et al. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found Symp 2004;256:53-69.
28. Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587-9.
29. Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005;44:670-6.
30. Sieper J, Van Der HD, Dougados M, et al. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:700-6.
31. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann NY Acad Sci 2006;1069:420-7.
32. Wijbrandts CA, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009;68:373-6.
33. Kawai VK, Stein CM, Perrien DS, et al. Effects of anti-tumor necrosis factor alpha agents on bone. Curr Opin Rheumatol 2012;24:576-85.
34. Chopin F, Garnero P, Le Henanff A, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:353-7.
35. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1495-9.
36. Kawai VK, Grijalva CG, Arbogast PG, et al. Initiation of Tumor Necrosis Factor Alpha (TNFalpha) antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res (Hoboken) 2013;65:1085-94.
37. Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-92.
38. Schett G, Redlich K, Hayer S, et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003;48:2042-51.